AnaptysBio - Anaptys Announces Participation in November Investor Conferences
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
ANB101
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Home
Anaptys Announces Participation in November Investor Conferences
Anaptys Announces Participation in November Investor Conferences
Home
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Home
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25